Vaccibody ( Vaccibody)

Primary tabs

Vaccibody's picture

Management

Contact Address

About Vaccibody

Vaccibody is a vaccine company with a vision to create the next generation of vaccines and immunotherapy. The technology use intelligent vaccine design based on complex immunological principles.

Vaccibody press release, blog etc

Thu, 03/04/2021 - 20:28 Vaccibody to adopt IFRS (International Financial Reporting Standards) and to explore a potential listing of its shares on the Nasdaq Global Market in the United States
Fri, 02/05/2021 - 14:46 Vaccibody will recruit new CFO
Mon, 04/01/2019 - 09:37 VACCIBODY AS AND NEKTAR THERAPEUTICS PRESENT NEW PRECLINICAL DATA FROM THEIR IMMUNO-ONCOLOGY COLLABORATION AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2019
Mon, 03/25/2019 - 08:22 POSITIVE 12-MONTH RESULTS FROM PHASE IIa CLINICAL STUDY IN HIGH GRADE CERVICAL DYSPLASIA PROVIDES PROOF-OF-CONCEPT FOR VACCIBODYS IMMUNOTHERAPY PLATFORM AND LEAD CANDIDATE VB1O.16
Wed, 02/27/2019 - 11:09 VACCIBODY AS TO PRESENT DATA ON VB10.NEO AND VB10.16 AT UPCOMING AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING
Thu, 02/14/2019 - 17:01 Vaccibody AS NOK 230 million (EUR 23.6 million) private placement successfully placed
Wed, 02/13/2019 - 17:52 VACCIBODY AS LAUNCHES A PRIVATE PLACEMENT OF NEW SHARES OF NOK 230 MILLION
Wed, 02/13/2019 - 17:06 VACCIBODY ANNOUNCES COLLABORATION TO STUDY VB10.16 AND ATEZOLIZUMAB (TECENTRIQ) IN ADVANCED CERVICAL CANCER
Tue, 09/25/2018 - 23:45 Positive results from the 6-months Interim analysis of the phase IIa clinical study in high grade cervical dysplasia provides Proof-of-Concept for Vaccibodys immunotherapy platform.
Wed, 09/19/2018 - 22:41 Vaccibody announces clinical collaboration agreement with Nektar Therapeutics for evaluation of Vaccibodys personalized cancer neoantigen vaccine in combination with Nektars CD-122-biased agonist, NKTR-214

InfoBox

HomePagewww.vaccibody.com